Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Net Income towards Common Stockholders (2016 - 2025)

Anika Therapeutics has reported Net Income towards Common Stockholders over the past 16 years, most recently at -$1.5 million for Q4 2025.

  • Quarterly Net Income towards Common Stockholders rose 92.21% to -$1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14000.0 through Mar 2026, up 100.03% year-over-year, with the annual reading at -$901000.0 for FY2025, 98.11% up from the prior year.
  • Net Income towards Common Stockholders was -$1.5 million for Q4 2025 at Anika Therapeutics, down from $846000.0 in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $17.1 million in Q4 2023 and troughed at -$28.1 million in Q3 2024.
  • The 5-year median for Net Income towards Common Stockholders is -$2.0 million (2024), against an average of -$2.8 million.
  • Year-over-year, Net Income towards Common Stockholders plummeted 845.88% in 2022 and then surged 188.56% in 2024.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$10.7 million in 2021, then soared by 156.56% to $6.1 million in 2022, then skyrocketed by 181.25% to $17.1 million in 2023, then tumbled by 213.33% to -$19.4 million in 2024, then soared by 92.21% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Net Income towards Common Stockholders are -$1.5 million (Q4 2025), $846000.0 (Q3 2025), and $677000.0 (Q2 2025).